Trial Profile

A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YH 002 (Primary)
Indications Advanced breast cancer; Bladder cancer; Colon cancer; Colorectal cancer; Malignant thymoma; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Eucure Biopharma

Most Recent Events

07 Jun 2022 Status changed from recruiting to completed.
06 Apr 2021 Planned primary completion date changed from 6 Mar 2021 to 25 Jul 2023.
11 Jan 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com